Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma.

Condition(s) studied

Investigational drug(s) / intervention(s)

Incidence of acute kidney injury: * Creatinine measurement before lymphodepletion chemotherapy, before CAR-T cells injection (day 0) and at day 1, day 3, day 5, day 7, day 10, day 14, day 21 and day 28. * AKI according to 2012 KDIGO.

Describe risk factors in AKI occurrence.: Comparison of caracteristics between participants with AKI and participants without AKI : * Baseline caracteristics of participants : age, gender, BMI (Body mass index), medical history… * Caracteristics of hematology disease : severity of lymphoma, previous treatments (chemotherapy, autologous/allogenic stem cell transplant), type of CAR-T cells (axi-cel, tisa-cel) * Other adverse affects : cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) * Use of nephrotoxic medications Informations found in medical field.

Focus on patient with chronic kidney disease at baseline: Looking at the subgroup with chronic kidney disease at baseline : are the outcomes different in this population ? Efficacity of CAR-T ? More adverse effects ?

Long term evolution after treatment by CAR-T cells: Creatinine measurement 1 year after CAR-T treatment. Informations found in medical field.

Study summary

The investigators want to describe the incidence of AKI after CAR-T cells therapy in B-cell lymphoma. With the aim of highlight risk factors in AKI occurrence. Then, look at outcomes in the subgroup with chronic kidney disease at baseline. Finally, the investigators will examine long term evolution of kidney function.

Eligibility

Primary outcome measure(s)

• Incidence of AKI after CAR-T cell therapy in B-cell lymphoma. In percentage, according to the 2012 KDIGO. — AKI from the day of the injection of CAR-T cells, until 28 days after the injection.

Trial sites (1)

More Hospices Civils de Lyon trials in France

Other trials for the same condition